Clinical and Antibody Responses After Influenza Immunization in Systemic Lupus Erythematosus

Publisher Website
Google Scholar
Abstract
After immunization with A/New Jersey/76 and A/Victoria/75 influenza vaccines, 11 patients with systemic lupus erythematosus were serially evaluated for changes in disease activity, serologic abnormalities and their capability to generate specific antibodies. One patient, with active disease, developed a diffuse, proliferative glomerulonephritis. None of the other patients or control subjects had significant local or systemic side effects. Significant levels of antibodies were generated to A/New Jersey/76 in 8 of the 11 patients and in 7 of 8 control subjects and to A/Victoria/75 in 7 of 11 patients and 5 of 8 control subjects. The geometric mean responses of total and Ig[immunoglobulin]G antibodies to each viral antigen were no different in patients with systemic lupus erythematosus than in control subjects. In patients with stable systemic lupus erythematosus, immunization with killed influenza viral vaccine appears to be safe and effective.

This publication has 3 references indexed in Scilit: